Replies to post #34 on Nkarta Inc (NKTX)

[jondoeuk]

In April, the FDA approved a protocol amendment to the trial of NKX101. This includes an overall shorter waiting period between enrolment, an additional two-dose regimen to increase patient convenience and to deliver more CAR-NK cells earlier in each cycle, and the earlier introduction of non haplo-related, off-the-shelf NKX101 in the ongoing dose finding cohort. The company aims to present initial data by year end.